In many cases, cell-penetrating peptides (CPPs) have been successfully used to deliver a large variety of cargoes into individual cell organelles, resulting in dramatically improved therapeutic outcomes.
The additional cells in the male ventral cord that express acr-5::dided2 did not overlap with the CP-expressing cells, but in many cases these cells were anterior to the CP neurons, suggesting that they could be CA neurons [ 18].
In many cases, however, cells are blocked in the pre-iPS cell state (Okita et al., 2007; Silva et al., 2008).
In many cases, tumor cells that lose normal adhesive constraints will enter cell cycle arrest and thus be refractory to many chemotherapeutic reagents.
However, in many cases stem cells differentiate in response to external signals, for instance by moving out of a stem cell niche (e.g. germ stem cells in C. elegans or stem cells in mammalian intestinal crypts).
However, in many cases, the cells in the patient became sick due to a combination of environment, genes and aging; so, 'rejuvenating' cells through iPSC generation may give the new source of tissue a new lifespan (see below for expansion of this idea).
In many cases malignant cells may seed other organs and expand following surgery to cause patient death.
In many cases, these cells may regress or become less active, with a concomitant decrease in expression of FAP, ADAM12, WISP1, and SOX11, and stabilization or regression of the clinical AF disease activity.
Cisplatin is often employed for the clinical treatment of patients with various tumors; however, in spite of high rates of clinical responses in many cases tumor cells activate an adaptive response to cisplatin that makes them less susceptible to the antiproliferative and cytotoxic effects to this drug.
Moreover, this anti-CD25 mAb treatment does not block the action of activated T cells, as it is reported in many cases, T-cell responses increased following this treatment [19], [22] [24].
